Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4079-4088

  Keating, Michael J ^a   O'Brien, Susan ^a   Albitar, Maher ^a   Lerner, Susan ^a   Plunkett, William ^a   Giles, Francis ^a   Andreeff, Michael ^a   Cortes, Jorge ^a   Faderl, Stefan ^a   Thomas, Deborah ^a   Koller, Charles ^a   Wierda, William ^a   Detry, Michelle A ^a   Lynn, Alice ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CD19 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; INTERLEUKIN 2 RECEPTOR ALPHA; ONDANSETRON; PARACETAMOL; PETHIDINE; RITUXIMAB; VALACICLOVIR; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VIDARABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW; BRONCHITIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELLULITIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOPENIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; GALLBLADDER CANCER; HAIR LOSS; HEALTH CARE ORGANIZATION; HEART DISEASE; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RASH; REMISSION; SEPTICEMIA; SIDE EFFECT; SINUSITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; CLINICAL TRIAL; MIDDLE AGED; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 23044510136     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.051     Document Type: Article

References (33)

1. Johnson S, Smith AG, Loffler H, et al: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: The French Cooperative Group on CLL. Lancet 347: 1432-1438, 1996
2. Keating MJ, O'Brien S, Lerner S, et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998
3. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
4. Yamauchi T, Nowak BJ, Keating MJ, et al: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001
5. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
6. Flinn IW, Byrd JC, Morrison C, et al: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000
7. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) that fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): Results of a phase III study (CLL4 protocol) of the German CLL Study Group. Proc Am Soc Hematol 102:72a, 2003 (abstr 243)
8. Maloney DG, Smith B, Rose A: Rituximab: Mechanism of action and resistance. Semin Oncol 29:2-9, 2002
9. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
10. Manshouri T, Do KA, Wang X, et al: Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101:2507-2513, 2003
11. Huhn D, von Schilling C, Wilhelm M, et al: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326-1331, 2001
12. O'Brien SM, Kantarjian H, Thomas DA, et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165-2170, 2001
13. Byrd JC, Murphy T, Howard RS, et al: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153-2164, 2001
14. Thomas DA, O'Brien S, Giles FJ, et al: Single agent Rituxan in early stage chronic lymphocytic leukemia (CLL). Proc Am Soc Hematol 98:364a, 2001 (abstr 1533)
15. Hainsworth JD, Litchy S, Barton JH, et al: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746-1751, 2003
16. Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20:2961-2966, 2000
17. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997
18. Di Gaetano N, Xiao Y, Erba E, et al: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114:800-809, 2001
19. Golay J, Zaffaroni L, Vaccari T, et al: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900-3908, 2000
20. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
21. Pfreundschuh MG, Trumper L, Ma D, et al: Randomized intergroup trial of first line treatment for patients < = 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: Early stopping after the first interim analysis. Proc Am Soc Clin Oncol 23:556, 2004 (abstr 6500)
22. Czuczman MS, Fallon A, Mohr A, et al: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29: 36-40, 2002
23. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
24. Keating MJ, O'Brien S, Robertson L, et al: Chronic lymphocytic leukemia: Correlation of response and survival. Leuk Lymphoma 11:167-175, 1993
25. Robertson LE, Huh YO, Butler JJ, et al: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29-36, 1992
26. Huh YO, Keating MJ, Saffer HL, et al: Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 116:437-443, 2001
27. Bryant J, Day R: Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383, 1995
28. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
29. Byrd JC, Rai K, Peterson BL, et al: The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005
30. Rawstron AC, Kennedy B, Evans PA, et al: Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98:29-35, 2001
31. Clavio M, Miglino M, Spriano M, et al: First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: Clinical results and molecular analysis of minimal residual disease. Eur J Haematol 61:197-203, 1998
32. Di Raimondo F, Giustolisi R, Cacciola E, et al: Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11:63-68, 1993
33. Bosch F, Ferrer A, Lopez-Guillermo A, et al: For the GELCAB: Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 119:976-984, 2002